Becton, Dickinson and Company (BDX) FY2026 Q1 P&L / Income Statement

Becton, Dickinson and Company (BDX) FY2026 Q1 P&L / Income Statement

Income statement for 2025-10-01 through 2025-12-31. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenues

5,252,000,000 US dollars

Cost of products sold

2,841,000,000 US dollars

Gross profit (calculated)

2,411,000,000 US dollars

Operating expenses (calculated)

1,859,000,000 US dollars

Operating Income

552,000,000 US dollars

Other income (expense), net (calculated)

negative 159,000,000 US dollars

Income Before Income Taxes

393,000,000 US dollars

Income tax provision

11,000,000 US dollars

Net Income

382,000,000 US dollars

BioPharma Systems

429,000,000 US dollars

Medical Essentials

1,595,000,000 US dollars

Connected Care

1,131,000,000 US dollars

Interventional

1,330,000,000 US dollars

Life Sciences

766,000,000 US dollars

Undisclosed (calculated)

1,000,000 US dollars

Integration, restructuring and transaction expense

111,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

Research and development expense

306,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

Selling and administrative expense

1,393,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

Other operating expense, net

50,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.